Purchase this article with an account.
Jose C. Rivera, Nicolas Sitaras, David Hamel, Ankush Madaan, Jean-Claude Honore, Baraa Noueihed, Martine Blais, Christian Quiniou, Przemyslaw Sapieha, Sylvain Chemtob; A Novel Allosteric Modulator of the IL-1 Receptor Prevents the Development of Oxygen-Induced Retinopathy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5889.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Inflammatory mediators can play an important role in the progression of retinopathy of prematurity (ROP). Interleukin-1β (IL-1β) is a cytokine that modulates the expression of the anti-angiogenic Semaphorin 3A (Sema3A). We hypothesized that an augmentation of IL-1β by activated microglia induced retinal vessels damage via Sema3A activation in oxygen-induced retinopathy (OIR). We investigated whether inhibiting the actions of IL-1β using a novel allosteric modulator of IL-1 receptor (IL-1R), labelled 101.10 prevented the vaso-obliteration (VO) and subsequent pathological neovascularization (NV) associated with OIR.
Sprague-Dawley rat pups subjected to vaso-obliteration (80% O2 from postnatal day (P)5 to 10) and pre-retinal neovascularization (cycling O2 during 14 days [50% and 10%] followed by room air until P18) models were treated with 101.10, IL-1Ra, or vehicle. The VO, NV and microglia activation were evaluated in retinal flat-mounts. Retinal mRNA expression was analyzed by qPCR. IL-1βsecretion in primary retinal microglia cultures subjected to hyperoxia (80% O2) or hypoxia (4% O2) was evaluated by ELISA. The pro-apoptotic effect of Sema3A expressed by retinal ganglion cells (RGC-5) stimulated with IL-1β was evaluated on rat endothelial cells (RBMVEC) in presence or absence of both IL-1 antagonists.
Upregulated mRNA expression of IL-1β, Sema3A and Iba-1 was detected in VO at P8 and during NV at P18. IP administration of both antagonists decreased microglial activation, IL-1β, Sema3A and Iba-1 expression and efficiently attenuated VO and pathological NV compared to vehicle. Oral administration effect of 101.10 was generally superior to that observed with oral IL-1Ra. An augmentation of IL-1β in the hyperoxic/hipoxic microglia cultures was found. Incremented release of Sema3A in RGC-5 treated with IL-1β augmented apoptosis in RBMVEC and was abolished in the presence of both IL-1 antagonists.
Our findings suggest that hyperoxia/hypoxia in the retina stimulate the activation of microglial cells that produce IL-1β which exacerbates microvascular injury via Sema3A. The IL-1 antagonist, 101.10, may represent a potential new therapeutic tool for preventing the inflammatory complications of ROP and help preserve vascular beds and decrease the detrimental angiogenesis associated with this disease.
This PDF is available to Subscribers Only